Browsing Schizophrenia and Psychotic Disorders by Subject "Schizophrenia"
Now showing items 21-40 of 41
-
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis
(2019-06)Introduction: In patients with schizophrenia, medication adherence is important for relapse prevention, and effective adherence monitoring is essential for treatment planning. A digital medicine system (DMS) has been ... -
Identifying effective characteristics of behavioral weight management interventions for people with serious mental illness: A systematic review with a qualitative comparative analysis
(2021-10)People with serious mental illness (SMI) have identified barriers to engaging in behavioral weight management interventions (BWMIs). We assessed whether BWMIs that addressed these barriers were more effective. First, we ... -
The impact of Patient and Public Involvement in the SlowMo study: Reflections on peer innovation
(2021-09)Background: The SlowMo study demonstrated the effects of SlowMo, an eight-session digitally supported reasoning intervention, on paranoia in a large-scale randomized-controlled trial with 362 participants with schizophre ... -
Is adjunctive CBT really effective for schizophrenia?
(2019-09)Although antipsychotic medication remains the mainstay of treatment for schizophrenia, medications alone are not always successful. Cognitive– behavioural therapy (CBT) is recommended as an adjunct to pharmacological ... -
Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders?
(2022-08)Antipsychotics are the cornerstone of schizophrenia management but they are not adequate in treating the negative and cognitive symptoms of the illness. The Cochrane review discussed in this commentary examines the safety ... -
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
(2021-12)The cognitive dysfunction experienced by patients with schizophrenia represents a major unmet clinical need. We believe that enhancing synaptic function and plasticity by targeting kalirin may provide a novel means to ... -
A life more ordinary: A peer research method qualitative study of the Feeling Safe Programme for persecutory delusions
(2022-07)Background: The Feeling Safe Programme is a cognitive therapy developed to improve outcomes for individuals with persecutory delusions. It is theoretically driven, modular and personalised, with differences in ... -
Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
(2023-06)Glutamatergic dysfunction is associated with failure to respond to antipsychotic medication in individuals with schizophrenia. Our objective was to combine neurochemical and functional brain imaging methods to investigate ... -
New drug targets in psychiatry: Neurobiological considerations in the genomics era
(2022-07)After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies. However, ... -
A Phenomenological Exploration of the Voices Reported by Borderline Personality and Schizophrenia Patients
(2021-06)Introduction: Over time, there have been different views regarding the verbal auditory hallucinations (VAHs) reported by borderline personality disorder (BPD) and schizophrenia patients. More recently, their similarity has ... -
Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis
(2018-01-30)Preclinical models propose that the onset of psychosis is associated with hippocampal hyperactivity, thought to be driven by cortical GABAergic interneuron dysfunction and disinhibition of pyramidal neurons. Recent ... -
Rare coding variants in ten genes confer substantial risk for schizophrenia
(2022-04)Rare coding variation has historically provided the most direct connections between gene function and disease pathogenesis. By meta-analysing the whole exomes of 24,248 schizophrenia cases and 97,322 controls, we implicate ... -
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis
(2023-11)Background: There is no consensus on defining relapse in schizophrenia, and scale-derived criteria with unclear clinical relevance are widely used. We aimed to develop an evidence-based scale-derived set of criteria to ... -
Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
(2022-02)IMPORTANCE Most evidence about efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict eligibility criteria, RCTs represent ... -
The service user experience of SlowMo therapy: A co-produced thematic analysis of service users' subjective experience
(2022-04)Objectives: SlowMo is the first blended digital therapy for paranoia, showing significant small-moderate reductions in paranoia in a recent large-scale randomized controlled trial (RCT). This study explored the subjective ... -
The side effect profile of Clozapine in real world data of three large mental hospitals
(2020-01)Objective: Mining the data contained within Electronic Health Records (EHRs) can potentially generate a greater understanding of medication effects in the real world, complementing what we know from Randomised control ... -
Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14–18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS)
(2019-07)Background: Adolescent-onset psychosis is associated with more severe symptoms and poorer outcomes than adult-onset psychosis. The National Institute for Clinical Excellence (NICE) recommend that adolescents with first ... -
The tail wagging the dog: the diagnostic accuracy of first rank symptoms COMMENTARY ON… COCHRANE CORNER
(2019-10)Outcomes for people with schizophrenia are improved by expedient diagnosis and specific treatment. ICD-11 and DSM-5 have reduced the importance of Schneider's first rank symptoms (FRS) in the diagnosis of schizophrenia; ... -
Targeting synaptic plasticity in schizophrenia: insights from genomic studies
(2021-08)Recent genomic findings identify many hundreds of genomic loci that are associated with schizophrenia. Consistent with data from the pregenomic era, genomic findings implicate synaptic function and plasticity as a tractable ... -
Understanding, treating, and renaming grandiosedelusions: A qualitative study
(2019-11)Background.Grandiose delusions are arguably the most neglected psychotic experience in research. Objectives.We aimed to discover from patients: whether grandiose delusions have harmful consequences; the psychological ...